| 1 | Disease-free survival as surrogate for overall survival in esophageal cancer: An individual patient data meta-analysis of neoadjuvant chemotherapy and chemoradiotherapy | 4.9 | 2 | Citations (PDF) |
| 2 | Innovative, early-phase clinical trials of drug–radiotherapy combinations | 27.4 | 14 | Citations (PDF) |
| 3 | Multimodal CustOmics: A unified and interpretable multi-task deep learning framework for multimodal integrative data analysis in oncology | 3.1 | 12 | Citations (PDF) |
| 4 | Confidence intervals of survival predictions with neural networks trained on molecular data | 2.6 | 1 | Citations (PDF) |
| 5 | Moving toward precision medicine to predict drug sensitivity in patients with metastatic breast cancer | 5.3 | 21 | Citations (PDF) |
| 6 | Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients | 6.5 | 12 | Citations (PDF) |
| 7 | Patient-Reported Quality of Life 6 Years After Breast Cancer | 6.6 | 11 | Citations (PDF) |
| 8 | Feasibility and Safety of the “One-Week Breast Radiation Therapy” Program | 1.6 | 3 | Citations (PDF) |
| 9 | Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors | 5.5 | 9 | Citations (PDF) |
| 10 | The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development | 9.9 | 57 | Citations (PDF) |
| 11 | Understanding and Overcoming Resistance to Selective FGFR Inhibitors across
FGFR2
-Driven Malignancies | 6.8 | 38 | Citations (PDF) |
| 12 | Sustained lymphocyte decreases after treatment for early breast cancer | 6.4 | 11 | Citations (PDF) |
| 13 | Molecular analysis for refractory rare cancers: Sequencing battle continues – learnings for the MOSCATO-01 study | 5.0 | 13 | Citations (PDF) |
| 14 | Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer | 25.1 | 51 | Citations (PDF) |
| 15 | CustOmics: A versatile deep-learning based strategy for multi-omics integration | 3.1 | 85 | Citations (PDF) |
| 16 | Favoring the hierarchical constraint in penalized survival models for randomized trials in precision medicine | 3.0 | 1 | Citations (PDF) |
| 17 | Resistance to Selective FGFR Inhibitors in
FGFR-
Driven Urothelial Cancer | 25.1 | 73 | Citations (PDF) |
| 18 | Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors | 6.8 | 22 | Citations (PDF) |
| 19 | A Case-Only Genome-Wide Interaction Study of Smoking and Bladder Cancer Risk: Results from the COBLAnCE Cohort | 3.8 | 0 | Citations (PDF) |
| 20 | Insights adjusting for non-adherence in randomized clinical trials: a reanalysis of an adjuvant trial of tamoxifen duration in early breast cancer | 5.5 | 2 | Citations (PDF) |
| 21 | A two‐stage drop‐the‐losers design for time‐to‐event outcome using a historical control arm | 1.2 | 1 | Citations (PDF) |
| 22 | Opérer ou non une lésion atypique du sein ? Prise en compte de l’anxiété dans l’aide à la décision partagée à partir d’une cohorte prospective de 300 patientes | 0.2 | 0 | Citations (PDF) |
| 23 | Penalized Poisson model for network meta‐analysis of individual patient time‐to‐event data | 1.7 | 4 | Citations (PDF) |
| 24 | Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer | 6.4 | 71 | Citations (PDF) |
| 25 | Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients | 9.9 | 33 | Citations (PDF) |
| 26 | Individual-specific networks for prediction modelling – A scoping review of methods | 2.5 | 6 | Citations (PDF) |
| 27 | Characterization of Depressive Symptoms Trajectories After Breast Cancer Diagnosis in Women in France | 6.6 | 46 | Citations (PDF) |
| 28 | Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer | 2.9 | 31 | Citations (PDF) |
| 29 | Near-Infrared Fluorescence Axillary Reverse Mapping (ARM) Procedure in Invasive Breast Cancer: Relationship between Fluorescence Signal in ARM Lymph Nodes and Clinical Outcomes | 3.8 | 6 | Citations (PDF) |
| 30 | Complex Disease Individual Molecular Characterization Using Infinite Sparse Graphical Independent Component Analysis | 1.9 | 3 | Citations (PDF) |
| 31 | Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab | 4.6 | 31 | Citations (PDF) |
| 32 | Informing the development of multidisciplinary interventions to help breast cancer patients return to work: a qualitative study | 2.2 | 12 | Citations (PDF) |
| 33 | Axillary reverse mapping using near-infrared fluorescence imaging in invasive breast cancer (ARMONIC study) | 0.9 | 10 | Citations (PDF) |
| 34 | Evaluating methods for Lasso selective inference in biomedical research: a comparative simulation study | 2.5 | 16 | Citations (PDF) |
| 35 | High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer | 13.7 | 100 | Citations (PDF) |
| 36 | Association of Adherence to Endocrine Therapy Among Patients With Breast Cancer and Potential Drug-Drug Interactions | 6.6 | 8 | Citations (PDF) |
| 37 | Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients | 2.0 | 11 | Citations (PDF) |
| 38 | EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer | 2.0 | 11 | Citations (PDF) |
| 39 | Biomarker Discovery and Validation: Statistical Considerations | 2.1 | 218 | Citations (PDF) |
| 40 | Impact of COVID-19 on healthcare organisation and cancer outcomes | 4.9 | 62 | Citations (PDF) |
| 41 | Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic | 33.0 | 2 | Citations (PDF) |
| 42 | OC-0646 Automatic tool for head and neck patient referral based on dose prediction with deep learning | 2.0 | 0 | Citations (PDF) |
| 43 | Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group | 3.8 | 16 | Citations (PDF) |
| 44 | Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue | 2.3 | 15 | Citations (PDF) |
| 45 | The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition | 9.9 | 222 | Citations (PDF) |
| 46 | Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction | 4.9 | 14 | Citations (PDF) |
| 47 | Validation of a new fully automated software for 2D digital mammographic breast density evaluation in predicting breast cancer risk | 3.4 | 8 | Citations (PDF) |
| 48 | A frequentist one-step model for a simple network meta-analysis of time-to-event data in presence of an effect modifier | 2.3 | 5 | Citations (PDF) |
| 49 | The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group | 6.4 | 241 | Citations (PDF) |
| 50 | Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study | 1.6 | 4 | Citations (PDF) |
| 51 | Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer | 6.8 | 158 | Citations (PDF) |
| 52 | Quality‐of‐life assessment in French patients with metastatic melanoma in real life | 4.0 | 14 | Citations (PDF) |
| 53 | Reactive stroma and trastuzumab resistance in HER2‐positive early breast cancer | 4.3 | 22 | Citations (PDF) |
| 54 | Meta‐analysis of clinical trials with competing time‐to‐event endpoints | 1.2 | 2 | Citations (PDF) |
| 55 | Prediction of Breast Cancer Treatment–Induced Fatigue by Machine Learning Using Genome-Wide Association Data | 2.9 | 21 | Citations (PDF) |
| 56 | Predictive classifier for intensive treatment of head and neck cancer | 4.0 | 20 | Citations (PDF) |
| 57 | Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group | 9.9 | 1,058 | Citations (PDF) |
| 58 | Body weight and return to work among survivors of early-stage breast cancer | 5.3 | 18 | Citations (PDF) |
| 59 | Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy | 6.5 | 26 | Citations (PDF) |
| 60 | Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells | 13.7 | 78 | Citations (PDF) |
| 61 | Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials | 6.4 | 20 | Citations (PDF) |
| 62 | Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non–small cell lung cancer | 4.9 | 89 | Citations (PDF) |
| 63 | Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group | 6.4 | 145 | Citations (PDF) |
| 64 | Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer | 6.4 | 173 | Citations (PDF) |
| 65 | Integrating expert’s knowledge constraint of time dependent exposures in structure learning for Bayesian networks | 5.7 | 13 | Citations (PDF) |
| 66 | A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer | 2.5 | 3 | Citations (PDF) |
| 67 | The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice | 4.9 | 195 | Citations (PDF) |
| 68 | Accounting for grouped predictor variables or pathways in high-dimensional penalized Cox regression models | 3.0 | 21 | Citations (PDF) |
| 69 | Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study | 2.3 | 24 | Citations (PDF) |
| 70 | Prospective Multicenter Study Validate a Prediction Model for Surgery Uptake Among Women with Atypical Breast Lesions | 2.3 | 9 | Citations (PDF) |
| 71 | EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer | 4.9 | 94 | Citations (PDF) |
| 72 | Prognostic value of tumour infiltrating lymphocytes (TILs) in patients with early-stage triple negative breast cancers (TNBC) in the absence of chemotherapy | 9.9 | 3 | Citations (PDF) |
| 73 | OC-0153 Immune infiltrate modulation induced by preoperative radiotherapy in breast cancer patients | 2.0 | 0 | Citations (PDF) |
| 74 | Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis | 9.9 | 209 | Citations (PDF) |
| 75 | An alternative trial-level measure for evaluating failure-time surrogate endpoints based on prediction error | 1.2 | 1 | Citations (PDF) |
| 76 | PO-0929 Focal boost dose escalated prostate SBRT on the Halcyon fast-rotating O-ring linac | 2.0 | 1 | Citations (PDF) |
| 77 | Fatigue and physical activity in cancer survivors: A cross‐sectional population‐based study | 2.6 | 42 | Citations (PDF) |
| 78 | IBS31.01 Endpoints and Trial Design for Oncogene Addicted NSCLC | 2.1 | 0 | Citations (PDF) |
| 79 | Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy | 9.9 | 216 | Citations (PDF) |
| 80 | Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy | 9.9 | 167 | Citations (PDF) |
| 81 | The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper | 5.0 | 256 | Citations (PDF) |
| 82 | A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses | 1.6 | 19 | Citations (PDF) |
| 83 | Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies | 2.3 | 11 | Citations (PDF) |
| 84 | Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis | 4.6 | 259 | Citations (PDF) |
| 85 | Multivariate joint frailty model for the analysis of nonlinear tumor kinetics and dynamic predictions of death | 1.7 | 10 | Citations (PDF) |
| 86 | Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door | 4.9 | 18 | Citations (PDF) |
| 87 | surrosurv: An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials | 4.6 | 32 | Citations (PDF) |
| 88 | A benchmark study of scoring methods for non-coding mutations | 4.7 | 24 | Citations (PDF) |
| 89 | biospear: an R package for biomarker selection in penalized Cox regression | 4.7 | 19 | Citations (PDF) |
| 90 | The European Society for Medical Oncology (ESMO) Precision Medicine Glossary | 9.9 | 149 | Citations (PDF) |
| 91 | ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors | 6.8 | 35 | Citations (PDF) |
| 92 | A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer | 9.9 | 58 | Citations (PDF) |
| 93 | Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer | 13.7 | 390 | Citations (PDF) |
| 94 | Precision medicine for patients with rare cancers: An effective strategy within the prospective MOSCATO trial | 9.9 | 1 | Citations (PDF) |
| 95 | Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays | 2.3 | 5 | Citations (PDF) |
| 96 | Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort | 4.9 | 42 | Citations (PDF) |
| 97 | Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks? | 4.9 | 27 | Citations (PDF) |
| 98 | Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer | 2.0 | 12 | Citations (PDF) |
| 99 | OC-0514: VMAT treatment planning for head-and-neck cancer with the novel fast-rotating linac halcyon | 2.0 | 0 | Citations (PDF) |
| 100 | PO-0741: Implementation of contouring guidelines can be achieved by online learning through a dummy run | 2.0 | 0 | Citations (PDF) |
| 101 | EP-2182: Use of 3D printing to generate patient-specific electron beam aperture blocks | 2.0 | 1 | Citations (PDF) |
| 102 | Robotic Prophylactic Nipple-Sparing Mastectomy with Immediate Prosthetic Breast Reconstruction: A Prospective Study | 2.3 | 104 | Citations (PDF) |
| 103 | Estimating causal effects of time-dependent exposures on a binary endpoint in a high-dimensional setting | 2.5 | 3 | Citations (PDF) |
| 104 | Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning | 13.7 | 145 | Citations (PDF) |
| 105 | Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors | 1.8 | 20 | Citations (PDF) |
| 106 | Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial | 9.9 | 58 | Citations (PDF) |
| 107 | A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups | 9.9 | 93 | Citations (PDF) |
| 108 | Joint model imputation to estimate the treatment effect on long-term survival using auxiliary events | 1.4 | 1 | Citations (PDF) |
| 109 | Exploring disparities in incidence and mortality rates of breast and gynecologic cancers according to the Human Development Index in the Pan-American region | 2.5 | 8 | Citations (PDF) |
| 110 | Authors’ Reply to Schoenfeld: “Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors”Drugs, 2017, 77, 1139-1140 | 11.4 | 1 | Citations (PDF) |
| 111 | High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial | 25.1 | 715 | Citations (PDF) |
| 112 | Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study | 27.4 | 259 | Citations (PDF) |
| 113 | Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis | 4.6 | 47 | Citations (PDF) |
| 114 | Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE) | 4.9 | 99 | Citations (PDF) |
| 115 | Predictors of responses to immune checkpoint blockade in advanced melanoma | 13.7 | 200 | Citations (PDF) |
| 116 | Societal challenges of precision medicine: Bringing order to chaos | 4.9 | 27 | Citations (PDF) |
| 117 | EP-1590: Can bolus range shifting improve plan quality in the IMPT of head and neck cancer? | 2.0 | 0 | Citations (PDF) |
| 118 | Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial | 6.8 | 131 | Citations (PDF) |
| 119 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors | 2.3 | 744 | Citations (PDF) |
| 120 | Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research | 2.3 | 637 | Citations (PDF) |
| 121 | Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial | 4.9 | 162 | Citations (PDF) |
| 122 | Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials | 2.5 | 12 | Citations (PDF) |
| 123 | Identification of biomarker‐by‐treatment interactions in randomized clinical trials with survival outcomes and high‐dimensional spaces | 1.2 | 37 | Citations (PDF) |
| 124 | Joint Model for Left-Censored Longitudinal Data, Recurrent Events and Terminal Event: Predictive Abilities of Tumor Burden for Cancer Evolution With Application to the FFCD 2000–05 Trial | 1.6 | 36 | Citations (PDF) |
| 125 | Empirical extensions of the lasso penalty to reduce the false discovery rate in high‐dimensional Cox regression models | 1.7 | 102 | Citations (PDF) |
| 126 | Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group | 4.8 | 285 | Citations (PDF) |
| 127 | The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene | 12.5 | 40 | Citations (PDF) |
| 128 | Méta-analyses en réseau : intérêt et limites en oncologie | 0.6 | 1 | Citations (PDF) |
| 129 | Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab | 14.3 | 91 | Citations (PDF) |
| 130 | Concordance between HER‐2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients | 4.1 | 7 | Citations (PDF) |
| 131 | Quelles exigences pour qu'un biomarqueur puisse être un critère de substitution acceptable ? | 0.6 | 1 | Citations (PDF) |
| 132 | Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers | 9.9 | 54 | Citations (PDF) |
| 133 | OC-0164: Integrate range shifting in immobilisation for proton therapy: 3D printed materials characterisation | 2.0 | 0 | Citations (PDF) |
| 134 | Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice | 9.9 | 40 | Citations (PDF) |
| 135 | Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis | 2.5 | 37 | Citations (PDF) |
| 136 | New insights into the evaluation of randomized controlled trials for rare diseases over a long‐term research horizon: a simulation study | 1.7 | 11 | Citations (PDF) |
| 137 | Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells | 3.8 | 26 | Citations (PDF) |
| 138 | The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence | 14.3 | 24 | Citations (PDF) |
| 139 | Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer | 9.9 | 42 | Citations (PDF) |
| 140 | Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma | 3.4 | 21 | Citations (PDF) |
| 141 | Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer | 2.3 | 38 | Citations (PDF) |
| 142 | Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma | 1.0 | 6 | Citations (PDF) |
| 143 | A Dual Model for Prioritizing Cancer Mutations in the Non-coding Genome Based on Germline and Somatic Events | 3.1 | 18 | Citations (PDF) |
| 144 | A joint model for the dependence between clustered times to tumour progression and deaths: A meta-analysis of chemotherapy in head and neck cancer | 1.6 | 44 | Citations (PDF) |
| 145 | Precision medicine for metastatic breast cancer—limitations and solutions | 70.7 | 311 | Citations (PDF) |
| 146 | A comparison between different prediction models for invasive breast cancer occurrence in the French E3N cohort | 2.3 | 14 | Citations (PDF) |
| 147 | Méta-analyses d’essais randomisés sur données individuelles dans le traitement des cancers ORL non métastatiques : principes, résultats, perspectives | 1.3 | 0 | Citations (PDF) |
| 148 | Méta-analyses d’essais randomisés sur données individuelles dans le traitement des cancers ORL non métastatiques : principes, résultats, perspectives | 1.3 | 0 | Citations (PDF) |
| 149 | Méta-analyses d’essais randomisés sur données individuelles dans le traitement des cancers ORL non métastatiques : principes, résultats, perspectives | 1.3 | 2 | Citations (PDF) |
| 150 | Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab | 14.3 | 565 | Citations (PDF) |
| 151 | Mining the coding and non-coding genome for cancer drivers | 8.6 | 16 | Citations (PDF) |
| 152 | Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology | 3.3 | 56 | Citations (PDF) |
| 153 | Statistical methods applied to omics data | 2.1 | 4 | Citations (PDF) |
| 154 | International study on inter-reader variability for circulating tumor cells in breast cancer | 4.7 | 47 | Citations (PDF) |
| 155 | Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data | 27.4 | 790 | Citations (PDF) |
| 156 | Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer | 9.9 | 224 | Citations (PDF) |
| 157 | Testing the treatment effect on competing causes of death in oncology clinical trials | 2.5 | 8 | Citations (PDF) |
| 158 | Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial | 9.9 | 1,152 | Citations (PDF) |
| 159 | Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients | 2.1 | 6 | Citations (PDF) |
| 160 | A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences | 4.1 | 42 | Citations (PDF) |
| 161 | Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis | 4.6 | 87 | Citations (PDF) |
| 162 | Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis | 4.9 | 150 | Citations (PDF) |
| 163 | Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data | 27.4 | 231 | Citations (PDF) |
| 164 | Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis | 4.6 | 162 | Citations (PDF) |
| 165 | Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial | 4.9 | 6 | Citations (PDF) |
| 166 | Genomic grade adds prognostic value in invasive lobular carcinoma | 9.9 | 68 | Citations (PDF) |
| 167 | Omics-based clinical trial designs | 2.1 | 17 | Citations (PDF) |
| 168 | Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement | 9.9 | 118 | Citations (PDF) |
| 169 | Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer | 4.6 | 149 | Citations (PDF) |
| 170 | Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis | 2.3 | 28 | Citations (PDF) |
| 171 | Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer | 2.3 | 25 | Citations (PDF) |
| 172 | CD4+ follicular helper T cell infiltration predicts breast cancer survival | 10.6 | 1,012 | Citations (PDF) |
| 173 | PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer | 2.3 | 84 | Citations (PDF) |
| 174 | Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer | 9.9 | 12 | Citations (PDF) |
| 175 | Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling | 6.8 | 353 | Citations (PDF) |
| 176 | Characterization and Clinical Evaluation of CD10+ Stroma Cells in the Breast Cancer Microenvironment | 6.8 | 52 | Citations (PDF) |
| 177 | Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease | 2.1 | 17 | Citations (PDF) |
| 178 | Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project—Part 2) | 2.1 | 71 | Citations (PDF) |
| 179 | A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints | 27.4 | 69 | Citations (PDF) |
| 180 | Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression | 2.9 | 53 | Citations (PDF) |
| 181 | 14O_PR Biology of Breast Cancer Diagnosed in Young Women: Pooled Gene Expression Analysis From 3522 Patients | 9.9 | 2 | Citations (PDF) |
| 182 | 21P Molecular Characterization of Early-Stage Her2-Overexpressing Breast Cancer (Her2+ Bc) Treated with Adjuvant Trastuzumab: Identification of Prognostic Groups | 9.9 | 1 | Citations (PDF) |
| 183 | 9O_PR Gene Modules and Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. A Pooled Analysis | 9.9 | 4 | Citations (PDF) |
| 184 | Integrating biomarkers in clinical trials | 3.0 | 141 | Citations (PDF) |
| 185 | Intégration des marqueurs pronostiques et prédictifs dans les essais cliniques | 0.2 | 0 | Citations (PDF) |
| 186 | Biomarker studies: a call for a comprehensive biomarker study registry | 70.7 | 114 | Citations (PDF) |
| 187 | Multidimensionality of microarrays: Statistical challenges and (im)possible solutions | 4.1 | 21 | Citations (PDF) |
| 188 | Activation of the phosphatidylinositol 3′-kinase/AKT pathway in neuroblastoma and its regulation by thioredoxin 1 | 2.3 | 23 | Citations (PDF) |
| 189 | HER2-Positive Circulating Tumor Cells in Breast Cancer | 2.3 | 194 | Citations (PDF) |
| 190 | Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status for the Administration of EGFR-TKIs in Non-Small Cell Lung Carcinoma [ERMETIC] Project—Part 1) | 2.1 | 52 | Citations (PDF) |
| 191 | Multiple testing of treatment‐effect‐modifying biomarkers in a randomized clinical trial with a survival endpoint | 1.7 | 12 | Citations (PDF) |
| 192 | DNA methylation profiling reveals a predominant immune component in breast cancers | 7.1 | 234 | Citations (PDF) |
| 193 | Multivariate Modelling Reveals Evidence of a Dose-Response Relationship in Phase 2 Studies of Single-Agent CarfilzomibBlood, 2011, 118, 1877-1877 | 4.8 | 10 | Citations (PDF) |
| 194 | Clinical Usefulness of Microarrays for Cancer Prognosis in 2010—Letter | 6.8 | 2 | Citations (PDF) |
| 195 | Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer | 16.5 | 767 | Citations (PDF) |
| 196 | CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence | 3.4 | 65 | Citations (PDF) |
| 197 | Genetic polymorphisms in 85 DNA repair genes and bladder cancer risk | 2.8 | 39 | Citations (PDF) |
| 198 | Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data | 27.4 | 164 | Citations (PDF) |
| 199 | Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis | 27.4 | 56 | Citations (PDF) |
| 200 | Investigating trial and treatment heterogeneity in an individual patient data meta‐analysis of survival data by means of the penalized maximum likelihood approach | 1.7 | 38 | Citations (PDF) |
| 201 | Variants in DNA double‐strand break repair and DNA damage‐response genes and susceptibility to lung and head and neck cancers | 4.3 | 23 | Citations (PDF) |
| 202 | Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas | 4.1 | 49 | Citations (PDF) |
| 203 | Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer | 9.9 | 31 | Citations (PDF) |
| 204 | Individual- and trial-level surrogacy in colorectal cancer | 1.6 | 73 | Citations (PDF) |
| 205 | Défis statistiques posés par les biopuces | 0.2 | 6 | Citations (PDF) |
| 206 | Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer | 16.9 | 341 | Citations (PDF) |
| 207 | Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer | 9.9 | 59 | Citations (PDF) |
| 208 | Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials | 9.9 | 76 | Citations (PDF) |
| 209 | Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 ‘triple-negative’ breast cancers | 9.9 | 70 | Citations (PDF) |
| 210 | Sodium/Iodide Symporter (NIS) Gene Expression Is the Limiting Step for the Onset of Thyroid Function in the Human Fetus | 4.0 | 86 | Citations (PDF) |
| 211 | Five-Gene Signature in Non–Small-Cell Lung Cancer | 34.5 | 3 | Citations (PDF) |
| 212 | Polymorphism discovery in 62 DNA repair genes and haplotype associations with risks for lung and head and neck cancers | 2.8 | 68 | Citations (PDF) |
| 213 | Gene expression profiling: Does it add predictive accuracy to clinical characteristics in cancer prognosis? | 4.9 | 96 | Citations (PDF) |
| 214 | Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data | 27.4 | 103 | Citations (PDF) |
| 215 | Expression of erythropoietin and its receptor in neuroblastomas | 4.0 | 26 | Citations (PDF) |
| 216 | Interpretation of microarray data in cancer | 5.5 | 86 | Citations (PDF) |
| 217 | Application of an acceptance sampling plan for post-production quality control of chemotherapeutic batches in an hospital pharmacy | 4.0 | 21 | Citations (PDF) |
| 218 | HEX, PAX-8 and TTF-1 gene expression in human thyroid tissues: a comparative analysis with other genes involved in iodide metabolism | 2.3 | 21 | Citations (PDF) |
| 219 | Expression and possible role of hPTTG1/securin in cutaneous malignant melanoma | 4.8 | 28 | Citations (PDF) |
| 220 | In reply to Drs. Huncharek and Kupelnick | 1.5 | 4 | Citations (PDF) |
| 221 | Gene Expression Profiling of Primary Cutaneous Melanoma and Clinical Outcome | 4.6 | 473 | Citations (PDF) |
| 222 | Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers | 9.9 | 59 | Citations (PDF) |
| 223 | Validation of Microarray Data by Quantitative Reverse-Transcriptase Polymerase Chain Reaction | 16.9 | 5 | Citations (PDF) |
| 224 | Bias in the estimation of false discovery rate in microarray studies | 4.7 | 72 | Citations (PDF) |
| 225 | Prediction of cancer outcome with microarrays: a multiple random validation strategy | 62.1 | 942 | Citations (PDF) |
| 226 | False discovery rate, sensitivity and sample size for microarray studies | 4.7 | 429 | Citations (PDF) |
| 227 | Random effects survival models gave a better understanding of heterogeneity in individual patient data meta-analyses | 3.7 | 32 | Citations (PDF) |
| 228 | Follicular Thyroid Tumors with the PAX8-PPARγ1 Rearrangement Display Characteristic Genetic Alterations | 3.4 | 84 | Citations (PDF) |
| 229 | Prediction of cancer outcome with microarrays: a multiple random validation strategy | 62.1 | 3 | Citations (PDF) |
| 230 | Modulation of Fluorouracil by Leucovorin in Patients With Advanced Colorectal Cancer: An Updated Meta-Analysis | 16.9 | 352 | Citations (PDF) |
| 231 | Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer | 16.5 | 320 | Citations (PDF) |
| 232 | Uncertain benefit from surgery in patients with lung metastases from breast carcinoma | 4.0 | 95 | Citations (PDF) |
| 233 | Identifying health conditions associated with an increased risk of pancreatic ductal adenocarcinoma at medium term in nationwide electronic health records of primary care physicians | 5.5 | 4 | Citations (PDF) |
| 234 | Acceptance of external control arms by HTA agencies: a review of oncology submissions in France, England, Germany and Norway from 2021 to 2023 | 5.5 | 3 | Citations (PDF) |
| 235 | Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial | 4.9 | 0 | Citations (PDF) |
| 236 | Robotic nipple-sparing mastectomy with immediate prosthetic reconstruction: A prospective study about 138 consecutive procedures | 0.5 | 0 | Citations (PDF) |
| 237 | Evaluating breast cancer screening consortium and MammoRisk plus polygenic risk score 313 for breast cancer risk prediction in UK Biobank | 4.9 | 4 | Citations (PDF) |
| 238 | Comprehensive radiotherapy quality assurance analysis from individual DICOM data in the HypoG-01 phase 3 trial | 2.0 | 4 | Citations (PDF) |
| 239 | Experience and Perceptions With a Phone‐Based Weight Loss Intervention Among Overweight and Obese Survivors of Breast Cancer Enduring Cancer‐Related Fatigue in France: A Qualitative Study Within a Randomized Clinical Trial | 1.9 | 0 | Citations (PDF) |
| 240 | Making sense of
TILs
: recommendations for morphological assessment of tumour‐infiltrating lymphocytes in gastro‐oesophageal carcinoma | 3.6 | 0 | Citations (PDF) |
| 241 | Development and internal validation of a clinical risk prediction model for pancreatic ductal adenocarcinoma in the UK Biobank | 4.9 | 0 | Citations (PDF) |
| 242 | Publication of clinical Ttial results: experience of an academic sponsor within the National Open Science Plan | 0.0 | 0 | Citations (PDF) |
| 243 | Use of clone-censor-weight to avoid immortal-time bias: a systematic methodological review | 0.0 | 0 | Citations (PDF) |
| 244 | Using permutation-based tests to evaluate adaptations to molecular treatment algorithms in randomized precision oncology trials | 0.0 | 0 | Citations (PDF) |
